150
Participants
Start Date
September 30, 2025
Primary Completion Date
December 31, 2027
Study Completion Date
December 31, 2028
Rocbrutinib
200mg qd PO. The treatment will continue until progressive disease, unacceptable toxicity, etc.
Bendamustine
Participants will receive a total of 6 cycles (a cycle being 28 days) 90 mg/m2 Bendamustine (IV infusion) on Days 1 and 2 of Cycles 1-6.
Rituximab
Participants will receive a total of 6 cycles (a cycle being 28 days) of 375 mg/m2 Rituximab (IV infusion) on Day 1 of each cycle.
Lenalidomide
20mg qd PO day 1-21
Anhui Cancer Hospital (West Branch of Anhui Provincial Hospital), Hefei
Beijing Shijitan Hospital, Beijing
Beijing Tongren Hospital, Beijing
National Cancer Center/Chinese Academy of Medical Sciences, Beijing
Peking University Third Hospital, Beijing
The First Affiliated Hospital of Chongqing Medical University, Chongqing
Fujian Cancer Hospital, Fuzhou
Affiliated Cancer Hospital of Guangzhou Medical University, Guangzhou
Guangdong Provincial People's Hospital, Guangzhou
Nanfang Hospital, Guangzhou
Meizhou People's Hospital, Meizhou
Affiliated Tumor Hospital of Guangxi Medical University, Nanning
The First Affiliated Hospital of Guangxi Medical University, Nanning
The Fourth Hospital of Hebei Medical University, Shijiazhuang
The First Affiliated Hospital of Henan University of Science and Technology, Luoyang
Henan Cancer Hospital, Zhengzhou
Henan Provincial People's Hospital, Zhengzhou
The First Affiliated Hospital of Zhengzhou University, Zhengzhou
Hubei Cancer Hospital, Wuhan
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan
The First Affiliated Hospital of Xiamen University, Xiamen
Hunan Cancer Hospital, Changsha
The Second Xiangya Hospital of Central South University, Changsha
Jiangsu Cancer Hospital, Nanjing
The First Affiliated Hospital of Soochow University, Suzhou
The Affiliated Hospital of Xuzhou Medical University, Xuzhou
Jiangxi Cancer Hospital, Nanchang
The First Affiliated Hospital of Nanchang University, Nanchang
The First Hospital of Jilin University, Jilin
The Second Affiliated Hospital of Dalian Medical University, Dalian
Liaoning Cancer Hospital, Shenyang
Shengjing Hospital of China Medical University, Shenyang
Linyi Cancer Hospital, Linyi
Fudan University Shanghai Cancer Center, Shanghai
Shanxi Bethune Hospital, Taiyuan
Shanxi Province Cancer Hospital, Taiyuan
Sichuan Cancer Hospital, Chengdu
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin
The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou
The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou
Zhejiang Cancer Hospital, Hangzhou
Guangzhou Lupeng Pharmaceutical Company LTD.
INDUSTRY